Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multi-Center Study Consisting of a Randomized, Placebo-Controlled Period, Followed by an Open-Label Extension Period to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults With Hidradenitis Suppurativa

NCT06993610 is registered in ClinicalTrials.gov with Zura Bio Inc as lead sponsor.

NCT NCT06993610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06993610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multi-Center Study Consisting of a Randomized, Placebo-Controlled Period, Followed by an Open-Label Extension Period to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults With Hidradenitis Suppurativa
Lead sponsor
Zura Bio Inc
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 16, 2025
Completion date
April 30, 2027
Enrollment
225 (estimated)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa (hs)